Quantcast

Latest Gilead Sciences Stories

2014-09-15 08:28:17

PITTSBURGH and HYDERABAD, India, Sept. 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc. under which Mylan has been licensed the non-exclusive rights to manufacture and distribute sofosbuvir and the investigational single tablet regimen of ledipasvir/sofosbuvir in 91 developing countries. Sofosbuvir is marketed by Gilead under the brand name Sovaldi®....

2014-09-03 04:21:58

VIENNA, September 3, 2014 /PRNewswire/ -- New US Subsidiary to be located in the Philadelphia Area Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative pathogens, today announced the appointment of Dr Colin Broom as Chief Executive Officer (CEO). Current CEO Ralf Schmid will remain a member of the...

2014-08-26 12:28:56

DUBLIN, Aug. 26, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Cytomegalovirus Retinitis Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Cytomegalovirus retinitis is a viral eye inflammation of the retina. The causative organism of this disease is cytomegalovirus, a herpes virus that attacks the photosensitive cells in the retina. This disease can lead to permanent blindness if left untreated. It affects...

2014-08-22 23:02:13

New research report “Global HIV Infection Drug Market & Pipeline Insight” worked out by Kuick Research is now available at MarketPublishers.com. London, UK (PRWEB) August 22, 2014 The improved access to antiretroviral drugs and treatments in the recent past, specifically in the developing world, has led to the decline in the rate of HIV infection and the number of deaths due to AIDS globally. However, despite the fact that HIV infection rates are declining, the number of new...

2014-08-22 16:23:16

LONDON, Aug. 22, 2014 /PRNewswire/ -- ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq(®) (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.(1) Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside...

2014-08-21 12:29:02

CHICAGO, Aug. 21, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN-Free Report), Gilead Sciences (Nasdaq:GILD-Free Report), Amgen (Nasdaq:AMGN-Free Report), Roche (OTC:RHHBY-Free Report) and Biogen (Nasdaq:BIIB-Free Report)....

2014-08-08 08:25:05

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, August 8, 2014 /PRNewswire/ -- Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Express Scripts Holding Company (NASDAQ: ESRX) and Tenet Healthcare Corp. (NYSE: THC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are...

2014-08-07 12:32:19

CHICAGO, Aug. 7, 2014 /PRNewswire/ -- Zacks Director of Research Sheraz Mian says, "The reduced negative revisions rate at this stage in the reporting cycle is the most notable positive element of this earnings season." http://photos.prnewswire.com/prnvar/20101027/ZIRLOGO Q3 Earnings Estimates Not Falling As Much The Q2 earnings season has turned out to be better relative to other recent reporting periods - the growth rate is better, more companies are beating estimates, and the very modest...

2014-08-01 12:28:49

CHICAGO, Aug. 1, 2014 /PRNewswire/ -- Zacks Director of Research Sheraz Mian says, "The overall picture emerging from the ongoing Q2 earnings season is notably better relative to what has been on offer in the recent past" http://photos.prnewswire.com/prnvar/20101027/ZIRLOGO Can the Earnings Rebound be Sustained? The overall picture emerging from the ongoing Q2 earnings season is notably better relative to what has been on offer in the recent past - growth is improving, more companies are...

2014-07-31 08:37:23

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, July 31, 2014 /PRNewswire/ -- Today, Analysts Review released its research reports regarding AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Horizon Pharma Inc. (NASDAQ: HZNP), Gilead Sciences Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV) and Exelixis Inc. (NASDAQ: EXEL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.